Article
Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.
The Journal of infectious diseases - 26 Aug 2022
Smith Robert A, Wu Vincent H, Song Jennifer, Raugi Dana N, Diallo Mbaye Khardiata, Seydi Moussa, Gottlieb Geoffrey S
Abstract excerpt
BACKGROUND: Integrase inhibitors (INIs) are a key component of antiretroviral therapy for human immunodeficiency virus-1 (HIV-1) and HIV-2 infection. Although INI resistance pathways are well-defined for HIV-1, mutations that emerge in HIV-2 in response to INIs are incompletely characterized. METHODS: We performed systematic searches of GenBank and HIV-2 drug resistance literature to identify treatment-associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.